Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05650190 · ClinicalTrials.gov registry record · NA

Spectacle Lens Visual Acuity Assessments Study

A NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.

Active
Registry status
NA
Development phase
51
Enrollment target
6
Study locations

NCT05650190 is a NA study of Myopia and Juvenile Myopia that is active but no longer recruiting, run by SightGlass Vision. The registered enrollment target is 51 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (81% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05650190, a NA study of Myopia and Juvenile Myopia, is active but no longer recruiting, sponsored by SightGlass Vision.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
51 participants
Enrollment target
6
Study locations

Study Summary

This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.

Interventions

  • DEVICE Novel spectacle lens design
  • DEVICE Spectacle lenses

Study Locations (6)

Florida

  • Sabal Eye Care - Longwood

Kansas

  • Kannarr Eye Care - Pittsburg

Missouri

  • Advanced Eyecare PC - Raytown

New York

  • SUNY School of Optometry - New York

Texas

  • Vision Optique - Houston

Utah

  • William J Bogus, OD, FAAO - Salt Lake City

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2022-12-08
Est. Completion 2026-03-31
Phase NA

Sponsor

SightGlass Vision

8 total trials

What the Registry Record Tells You About NCT05650190

The ClinicalTrials.gov registry entry for NCT05650190 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (81% lower). The listed sponsor is SightGlass Vision, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Novel spectacle lens design is the first listed.

NCT05650190 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Florida, Kansas, Missouri.

Frequently Asked Questions

What is clinical trial NCT05650190 about?

NCT05650190 is a clinical study titled "Spectacle Lens Visual Acuity Assessments Study". This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.

What is the current status of trial NCT05650190?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 51 participants. The study started on 2022-12-08. Estimated completion is 2026-03-31.

What conditions does trial NCT05650190 study?

This clinical trial studies the following conditions: Myopia, Juvenile Myopia, Myopia Progression.

What interventions are being tested in trial NCT05650190?

The interventions under investigation include: Novel spectacle lens design (DEVICE), Spectacle lenses (DEVICE).

Who is sponsoring clinical trial NCT05650190?

This trial is sponsored by SightGlass Vision, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05650190 being conducted?

This trial has 6 study locations across Florida, Kansas, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.